This deal will combine Biognosys’ expertise in unbiased biomarker discovery technologies and solutions with Siemens Healthineers’ biomarker assay development, lab testing and commercialisation capabilities.
Biognosys CEO and founder Oliver Rinner said: “With this agreement, we can enable our biopharmaceutical customers to use the power of our proprietary discovery proteomics solution for novel biomarker identification and bring these biomarkers into clinical applications with Siemens Healthineers’ diagnostic assay development expertise.”
The partnership will use Biognosys’ proprietary Hyper Reaction Monitoring (HRM) mass spectrometry technology to quantify numerable proteins simultaneously from a wide range of clinical sample types.
HRM provides an unparalleled depth of proteome coverage with reproducible and exact measurements to distinguish actionable biomarkers that will help in clinical decision-making.
The solution can be used with high throughput in large-scale studies which include thousands of samples.
The collaboration aims to discover novel biomarker using the HRM technology, which can then be developed into validated biomarker tests with potential clinical application. These applications could include clinical trials as well as In Vitro Diagnostics development programmes.
The companies intend to run this biomarker development out of Siemens Healthineers’ clinical laboratory in California, US.
Siemens California healthcare laboratory head Sebastian Kronmueller said: “We are excited about this relationship with Biognosys because their expertise and unique biomarker discovery capabilities are very complementary to our end-to-end diagnostic solutions for our biopharmaceutical customers.”